Unicycive Therapeutics, Inc. (UNCY) stock
Close on Nov 18, 2026Market cap $99.44MP/E –Yield –
Earnings
Unicycive Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Unicycive Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q3 FY2026ended Sep 30, 2026 | Oct 27, 2026Expected | – | – | – | – |
| Q2 FY2026ended Jun 30, 2026 | Aug 12, 2026before the open | – | – | -$0.06 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 12, 2026before the open | – | – | -$0.54 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 30, 2026before the open | – | – | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Oct 28, 2025before the open | – | – | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 14, 2025before the open | – | – | -$0.52 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 14, 2025before the open | – | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 31, 2025after the close | – | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 13, 2024before the open | – | – | -$0.05 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 14, 2024before the open | – | – | -$0.15 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 13, 2024after the close | – | – | -$0.61 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 29, 2024after the close | – | – | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 14, 2023after the close | $0 | -100.0% | -$0.13 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 15, 2023after the close | – | – | -$0.29 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 16, 2023during market hours | $700.00K | – | -$0.97 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 31, 2023before the open | – | – | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 14, 2022during market hours | $1.00M | – | -$0.37 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 15, 2022after the close | – | – | -$0.24 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 12, 2022before the open | – | – | -$0.24 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 31, 2022during market hours | – | – | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 12, 2021before the open | – | – | -$0.37 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 16, 2021before the open | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Unicycive Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Unicycive Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Unicycive Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- Results
- Results
- Results
- Results
- Results
- Results
- News
- Results
- News
- News
- News
- Results
- Results
See a number that looks wrong?